Trelagliptin succinate|1029877-94-8|(曲格列汀琥珀酸盐; SYR-472 succinate)-陌孚医药/Medlife

您当前的位置：

Trelagliptin succinate (Synonyms: 曲格列汀琥珀酸盐; SYR-472 succinate)

目录号: PL13888 纯度: ≥99%

CAS No. :1029877-94-8

商品编号	规格	价格	会员价
PL13888-5mg	5mg	¥803.00	请登录
PL13888-10mg	10mg	¥1285.00	请登录
PL13888-50mg	50mg	¥1928.00	请登录
PL13888-100mg	100mg	¥2571.00	请登录
PL13888-200mg	200mg	询价	询价
PL13888-500mg	500mg	询价	询价
PL13888-10mM*1mLinDMSO	10mM*1mLinDMSO	¥884.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Trelagliptin succinate
中文别名	琥珀酸曲格列汀;SRY-472 琥珀酸曲格列汀;SRY-472原药;SYR472 抑制剂;琥珀酸盐曲格列汀;曲格列汀琥珀酸盐;曲格列汀2;曲格列汀琥珀酸;2-[[6-[(3R)-3-氨基-1-哌啶基]-3,4-二氢-3-甲基-2,4-二氧代-1(2H)-嘧啶基]甲基]-4-氟-苯甲腈琥珀酸盐;-[[2'-(2,5-二氢-5-氧代-1,2,4-恶二唑-3-基)[1,1'-联苯]-4-基]甲基]-2-乙氧基-1H-苯并咪唑-7-羧酸 (5-甲基;SRY-472
英文名称	Trelagliptin succinate
英文别名	SRY-472;2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile,butanedioic acid;SYR 472;SYR-472;Trelagliptin (succinate);Trelagliptin succinat;Trelagliptin Succinate;Trelagliptin succinate(SYR 111472 succinate);SureCN878010;SYR 111472 succinate;SYR-111472 Succinate;SYR472 succinate;SYR-472 succinate;Trelagliptin succinate - SYR 111472 succinate;Trelagliptin succinate [USAN];Telagliptin Succinate;Trelagliptin Succinate API;SYR472;(R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)-4-fluorobenzonitrile succinate;2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile;butanedioic acid;4118932Z90;SYR111472 SUCCINATE;AK198895;Zafatek (TN);trelaglipti;zafatek;CHE;Trelagliptin succinate
Cas No.	1029877-94-8
分子式	C₂₂H₂₆FN₅O₆
分子量	475.47
包装储存	4°C, sealed storage, away from moistur In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

产品详情

Trelagliptin (SYR-472) succinate 是一种有效的，具有口服活性 DPP-4 抑制剂，IC₅₀ 为4 nM。Trelagliptin (SYR-472) succinate 改善体内血糖控制，可用于2 型糖尿病 (T2DM) 的研究。

生物活性

Trelagliptin (SYR-472) succinate is a potent, orally active and highly selective DPP-4 inhibitor with an IC 50 of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM).

性状

Solid

IC50 & Target[1][2]

IC50: 4 nM (DPP-4)

体外研究(In Vitro)

Dipeptidyl peptidase-4 (DPP-4) is one of the widely explored novel targets for type 2 diabetes mellitus (T2DM) strategy to preserve the endogenous glucagon like peptide (GLP)-1 activity by inhibiting the DPP-4 action.
Trelagliptin exhibits potent inhibitory activity toward DPP-4 prepared from Caco-2 cells with an IC50 value of 5.4 nM. Trelagliptin also inhibits human, dog, and rat plasma DPP-4 activity with IC50 values of 4.2 nM, 6.2 nM, and 9.7 nM, respectively.
Trelagliptin is highly selective for DPP-4 and displays IC50 values >100,000 nM corresponding to >10,000-fold selectivity over DPP-2, DPP-8, DPP-9, PEP and FAPα activities. Trelagliptin shows DPP4 selective about 4- and 12-fold more potent than alogliptin (HY-A0023) and sitagliptin (HY-13749), respectively.

体内研究(In Vivo)

Trelagliptin (oral gavage; 7 mg/kg; single dose) shows sustained PD effect in dogs and gives >80% inhibition of DPP-4 activity even after 24h.
Trelagliptin (oral gavage; 3 mg/kg; single dose; 60 min prior to oral glucose) significantly improves the glucose tolerance capacity by decreasing the AUC 0?120min of 19.3% compared with the vehicle group in ob/ob mice.
Trelagliptin (oral gavage; 10 mg/kg; once a week; 8 weeks) caused significant reductions in fasting blood glucose (FBG) levels, and the average reduction during the entire treatment period is 16.8% compared to the control.It also increases insulin level and raised it by 1.7-fold in AUC 0?120min in ob/ob mice.
has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moistur In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

ClinicalTrial

参考文献

[1]. Bhumika D Patel, et al. Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors. Eur J Med Chem. 2014 Mar 3;74:574-605.
[2]. Charles E Grimshaw, et al. Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism. PLoS One. 2016 Jun 21;11(6):e0157509.

溶解度数据	In Vitro: H₂O : 100 mg/mL (210.32 mM; Need ultrasonic)DMSO : ≥ 50 mg/mL (105.16 mM)

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation